Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Keybanc said Nike’s outlook is further clouded by growing uncertainty around operations in China and EMEA, as well as management transition.
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
David Denton will replace Matthew Friend, who will remain at the company until 4 September to assist with the handover.
Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”
Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant overall survival benefit over docetaxel in the overall population, while the U.S. FDA approved IBRANCE as a maintenance option for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. Together, the mixed lung cancer data and the expanded IBRANCE...
In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.
The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a
With an annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) is included among the 12 Best S&P 500 Stocks to Buy for Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]
(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a
The sports apparel giant is turning to new financial leadership as it looks to make more progress with its “Win Now” turnaround strategy.
Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective August 17, succeeding Matthew Friend, who will remain with the company through September 4 to support the transition. According to the...
Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.
David Denton, who has led Pfizer's finances since 2022, will take over as Nike's chief financial officer on Aug. 17
Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.
IBB, Novartis, Pfizer and Eli Lilly's have been highlighted in this Investment Ideas article.
Nike (NYSE:NKE) has appointed David M. Denton as its incoming Chief Financial Officer. Denton, who has held senior finance roles at Pfizer and Lowe's, is set to succeed current CFO Matthew Friend. The transition comes as Nike continues a multiyear turnaround and addresses operational challenges and skepticism about its execution. Nike, a major global sportswear and footwear company, is in the middle of a turnaround that includes operational adjustments and a renewed focus on execution. The...
Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.
David Denton will join Nike Inc. as executive vice president and chief financial officer on Aug. 17, succeeding Matthew Friend.
Don't wait until they recover to initiate positions.